Serbia’s pharmaceutical market is rising because it sits at the intersection of public healthcare demand, ageing demographics, higher prescription medicine consumption, import dependence, regional export potential, and renewed manufacturing investment.
In Q1 2026, Serbia exported €172.3m of medicinal and pharmaceutical products, up 15.7% year-on-year, while imports reached €520.0m, down 15.3% from Q1 2025. The sector still recorded a deficit of €347.7m, but the improvement from €465.3m a year earlier shows that local production and export capacity are gaining ground.
The wider market has also expanded sharply. Serbia’s pharmaceutical market reached around €2.07bn in 2025, compared with €1.52bn in 2022, implying growth of roughly 36% over three years. Prescription medicines were the main engine, with the Rx segment adding about €137m in new sales, and original prescription medicines accounting for most of the value growth.
The key structural point is that Serbia remains a major pharma importer. In 2024, Serbia imported about $1.5bn of medicaments, up from $1.29bn in 2023, the highest level in the available series. Exports of medicaments were much smaller, at about $363m in 2024, after a peak of $444m in 2023.
That gap creates the opportunity. Serbia has strong domestic players, especially Hemofarm, Galenika, Zdravlje Actavis/Teva, PharmaSwiss, and a wider base of distributors, wholesalers, pharmacies and clinical-service companies. Hemofarm, part of STADA, remains the central industrial anchor, with production in Vršac and a regional export footprint. The Serbian government highlighted Hemofarm in March 2026 as a major contributor to economic growth and a signal for further investment in high value-added production.
The strongest market drivers are clear. First, Serbia’s ageing population is increasing demand for chronic therapies, cardiovascular medicines, diabetes care, oncology, neurology and hospital pharmaceuticals. Second, public healthcare spending and reimbursement dynamics are pushing volume growth in prescription medicines. Third, inflation and higher-value therapies are raising market value faster than unit consumption. Fourth, Serbia’s CEFTA and Western Balkan position gives local manufacturers a natural regional market. Fifth, EU-aligned regulation, serialization, GMP standards and pharmacovigilance requirements are making Serbian plants more attractive as nearshore production bases.
The fastest-growing commercial segments are likely to be Rx original medicines, generics, biosimilars, oncology, cardiometabolic therapies, hospital medicines, vaccines and biologics distribution, consumer health, supplements, and private-label pharmacy products. Generics remain important because Serbia’s healthcare system needs cost control, while originals and specialty therapies are driving value growth.
For investors, the opportunity is not only in drug manufacturing. It also sits in contract manufacturing, packaging, cold-chain logistics, pharma warehousing, clinical trials, regulatory affairs, pharmacovigilance, quality-control labs, medical distribution, and digital pharmacy infrastructure. Serbia’s cost base, scientific talent pool, regional access and industrial tradition give it a credible position, but the sector still depends heavily on imported APIs, advanced biologics, specialty medicines and patented therapies.
The 2026 investment thesis is therefore simple: Serbia is not yet a large pharmaceutical power, but it is becoming a more important regional production, distribution and healthcare-demand platform. The market is growing, imports remain high, exports are improving, and local manufacturing has enough industrial depth to capture more value if Serbia moves further into high-standard generics, biosimilars, sterile production, packaging, testing and regional supply-chain services.
